598 related articles for article (PubMed ID: 21149773)
21. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.
Murray CD; Wood D; Allgar V; Walters G; Gale RP
Eye (Lond); 2014 Oct; 28(10):1218-22. PubMed ID: 25081290
[TBL] [Abstract][Full Text] [Related]
22. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
23. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
24. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
25. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
Demirel S; Yanik O; Batioglu F; Ozmert E
Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
[TBL] [Abstract][Full Text] [Related]
26. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
27. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections.
Shoeibi N; Ghosi Z; Jafari H; Omidtabrizi A
Int Ophthalmol; 2021 Mar; 41(3):1081-1090. PubMed ID: 33389369
[TBL] [Abstract][Full Text] [Related]
28. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents.
Pershing S; Bakri SJ; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(5):460-4. PubMed ID: 24044708
[TBL] [Abstract][Full Text] [Related]
29. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
[TBL] [Abstract][Full Text] [Related]
30. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
Hariprasad SM; Shah GK; Blinder KJ
Am J Ophthalmol; 2006 Jan; 141(1):200-1. PubMed ID: 16387003
[TBL] [Abstract][Full Text] [Related]
31. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
32. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection.
El Chehab H; Le Corre A; Agard E; Ract-Madoux G; Coste O; Dot C
Eur J Ophthalmol; 2013; 23(3):277-83. PubMed ID: 23161177
[TBL] [Abstract][Full Text] [Related]
33. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
35. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
36. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?
Kim D; Nam WH; Kim HK; Yi K
J Glaucoma; 2014 Sep; 23(7):446-8. PubMed ID: 23632401
[TBL] [Abstract][Full Text] [Related]
37. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
38. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
39. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
40. Persisent ocular hypertension following intravitreal ranibizumab.
Bakri SJ; McCannel CA; Edwards AO; Moshfeghi DM
Graefes Arch Clin Exp Ophthalmol; 2008 Jul; 246(7):955-8. PubMed ID: 18425523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]